BRIEF-Acelyrin Announces Topline Results From Phase 2B/3 Study Of Izokibep For The Treatment Of Uveitis

Reuters2024-12-11

Dec 10 (Reuters) - ACELYRIN Inc SLRN.O:

ACELYRIN, INC. ANNOUNCES TOPLINE RESULTS FROM PHASE 2B/3 STUDY OF IZOKIBEP FOR THE TREATMENT OF UVEITIS
ACELYRIN INC - PHASE 2B/3 TRIAL OF IZOKIBEP DID NOT MEET PRIMARY ENDPOINT
ACELYRIN INC - COMPANY TO INITIATE PHASE 3 PROGRAM FOR LONIGUTAMAB IN Q1 2025
ACELYRIN INC - TO CEASE INTERNAL INVESTMENT IN IZOKIBEP DEVELOPMENT
ACELYRIN INC - COMPANY PROJECTS CASH RUNWAY TO MID-2027

Source text: nGNXbvW5qx

Further company coverage: SLRN.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2490027987?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-11 06:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2490027987","market":"us","top_or_hot":-1,"title":"BRIEF-Acelyrin Announces Topline Results From Phase 2B/3 Study Of Izokibep For The Treatment Of Uveitis","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Acelyrin Announces Topline Results From Phase 2B/3 Study Of Izokibep For The Treatment Of Uveitis</title></head><body><p><span>Dec 10 (Reuters)</span><span> - </span>ACELYRIN Inc <span>SLRN.O</span>:</p><ul><li><p>ACELYRIN, INC. ANNOUNCES TOPLINE RESULTS FROM PHASE 2B/3 STUDY OF IZOKIBEP FOR THE TREATMENT OF UVEITIS</p></li><li><p>ACELYRIN INC - PHASE 2B/3 TRIAL OF IZOKIBEP DID NOT MEET PRIMARY ENDPOINT</p></li><li><p>ACELYRIN INC - COMPANY TO INITIATE PHASE 3 PROGRAM FOR LONIGUTAMAB IN Q1 2025</p></li><li><p>ACELYRIN INC - TO CEASE INTERNAL INVESTMENT IN IZOKIBEP DEVELOPMENT</p></li><li><p>ACELYRIN INC - COMPANY PROJECTS CASH RUNWAY TO MID-2027</p></li></ul><p>Source text: <span>nGNXbvW5qx</span></p><p>Further company coverage: <span>SLRN.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Acelyrin Announces Topline Results From Phase 2B/3 Study Of Izokibep For The Treatment Of Uveitis</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Acelyrin Announces Topline Results From Phase 2B/3 Study Of Izokibep For The Treatment Of Uveitis\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-11 06:26 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241210:nTUA8XF1M1:1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BRIEF-Acelyrin Announces Topline Results From Phase 2B/3 Study Of Izokibep For The Treatment Of UveitisDec 10 (Reuters) - ACELYRIN Inc SLRN.O:ACELYRIN, INC. ANNOUNCES TOPLINE RESULTS FROM PHASE 2B/3 ...</p>\n\n<a href=\"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241210:nTUA8XF1M1:1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241210:nTUA8XF1M1:1","article_id":"2490027987","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2490027987","pubTimestamp":1733869568,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Acelyrin Announces Topline Results From Phase 2B/3 Study Of Izokibep For The Treatment Of UveitisDec 10 (Reuters) - ACELYRIN Inc SLRN.O:ACELYRIN, INC. ANNOUNCES TOPLINE RESULTS FROM PHASE 2B/3 S","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","SLRN":"Acelyrin, Inc."},"translate_title":"BRIEF-Acelyrin宣布Izokibep治疗葡萄膜炎的2B/3期研究的主要结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SLRN":0.9},"content_text":"BRIEF-Acelyrin Announces Topline Results From Phase 2B/3 Study Of Izokibep For The Treatment Of UveitisDec 10 (Reuters) - ACELYRIN Inc SLRN.O:ACELYRIN, INC. ANNOUNCES TOPLINE RESULTS FROM PHASE 2B/3 STUDY OF IZOKIBEP FOR THE TREATMENT OF UVEITISACELYRIN INC - PHASE 2B/3 TRIAL OF IZOKIBEP DID NOT MEET PRIMARY ENDPOINTACELYRIN INC - COMPANY TO INITIATE PHASE 3 PROGRAM FOR LONIGUTAMAB IN Q1 2025ACELYRIN INC - TO CEASE INTERNAL INVESTMENT IN IZOKIBEP DEVELOPMENTACELYRIN INC - COMPANY PROJECTS CASH RUNWAY TO MID-2027Source text: nGNXbvW5qxFurther company coverage: SLRN.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.0","shortVersion":"4.30.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2490027987"}